Why Choose the Aflac Cancer and Blood Disorders Center
As one of the top pediatric blood and marrow transplant (BMT) programs in the country, we provide expertise in autologous and allogeneic transplants for a wide variety of cancers and disorders of the blood, immune system and metabolism. We are international leaders in the treatment of high risk leukemia, BMT for sickle cell disease as well in immune dysregulation and immune deficiency.
We provide a wide range of cutting-edge treatments, including gene therapy, chimeric antigen receptor T (CAR-T) therapy, haploidentical (half-matched donors), and novel approaches for the prevention and management of graft-versus-host disease (GVHD). Our patients have among the best survival rates in the country, which is a testament to our careful attention to family-centered care. In fact, we have consistently exceeded the predicted benchmark of survival for our mix of patients.
Highlights of our Blood and Marrow Transplant Program
- The Aflac Cancer and Blood Disorders Center is one of the largest pediatric blood and marrow transplant programs in the country, performing more than 70 lifesaving BMTs in 2021, one of the largest volumes in the country.
- We have been recognized as a national leader in transplanting patients with sickle cell disease.
- Our 100-plus-day survival rates are better than the national average for autologous and allogeneic BMTs.
- We have a growing unique, multidisciplinary Immunohematology Program focused on curing immunodeficiencies and immune dysregulation through BMT.
- We are experts in the treatment of high risk leukemia, and provide cutting-edge treatment including CAR-T cell therapy.
- We have expertise in performing transplantation from half-matched related donors, and mismatched unrelated donors, making BMTs available to patients without a matched sibling or a matched related donor.
- We have experts in the treatment of acute and chronic GVHD, including offering comprehensive care within our chronic GVHD clinic.
- We provide access to and lead clinical trials for patients undergoing transplantation and cellular therapy.
Click the link for more information about our Blood and Marrow Transplant Program and research.
Our BMT team:
- Shanmuganathan Chandrakasan, MD
- Lisa Daley-Bauer, PhD
- Ann Haight, MD
- Edwin Horwitz, MD, PhD
- Kathryn Leung, MD, FAAP, Clinical Director
- Wayne Liang, MD, MS, FAMIA, FAAP
- Suhag Parikh, MD
- Muna Qayed, MD, MSCR, Section Director of BMT
- Michelle Schoettler, MD
- Elizabeth Stenger, MD, MSc
- Benjamin Watkins, MD
- Kirsten Williams, MD